Delta-like Ligand 3 (DLL3) is rapidly establishing a position as one of the promising targets in the treatment of aggressive Neuroendocrine Cancers (NECs), including Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), and Large-Cell Neuroendocrine Carcinoma (LCNEC), where existing treatments deliver only limited benefit. After being dismissed following high-profile failures of Rova-T and AMG 119, DLL3 made a comeback in 2024 with Amgen’s IMDELLTRA, the first approved DLL3-directed therapy, which reignited interest in the target and reshaped the treatment landscape. Now, the pipeline is surging with innovation: bispecific antibodies, Chimeric Antigen ...
